Bausch Health Companies (TSE:BHC) Raised to Hold at Raymond James

Raymond James upgraded shares of Bausch Health Companies (TSE:BHC) to a hold rating in a research report report published on Wednesday morning, Zacks.com reports.

Bausch Health Companies Stock Down 1.8 %

Shares of TSE:BHC opened at C$10.10 on Wednesday. Bausch Health Companies has a 52 week low of C$8.32 and a 52 week high of C$15.43. The company has a 50 day moving average price of C$9.20 and a two-hundred day moving average price of C$10.95. The company has a market capitalization of C$3.70 billion, a PE ratio of -5.98, a PEG ratio of 0.21 and a beta of 0.90. The company has a debt-to-equity ratio of 7,583.76, a quick ratio of 0.58 and a current ratio of 1.23.

Bausch Health Companies (TSE:BHC) last posted its quarterly earnings data on Thursday, May 2nd. The company reported C$0.80 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C$1.02 by C($0.22). Bausch Health Companies had a negative return on equity of 686.52% and a negative net margin of 5.07%. The firm had revenue of C$2.90 billion for the quarter, compared to the consensus estimate of C$2.98 billion. Analysts forecast that Bausch Health Companies will post 4.85 earnings per share for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.